EPAS1 and anemia (phenotype): Taken together, these data demonstrate FG‐4592 treatment increases FPN expression mainly through HIF2α binding to the HREs on the promoter of FPN (Figure 6R), and overexpressing duodenal Hif2α could directly trigger Fpn expression and rescue hepcidin‐activated anemias.